Division of Biostatistics and Bioinformatics, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Department of Biostatistics, Johns Hopkins University School of Public Health, Baltimore, Maryland, USA.
Alzheimers Dement. 2020 Nov;16(11):1524-1533. doi: 10.1002/alz.12140. Epub 2020 Jul 30.
Identifying cognitively normal individuals at high risk for progression to symptomatic Alzheimer's disease (AD) is critical for early intervention.
An AD risk score was derived using unsupervised machine learning. The score was developed using data from 226 cognitively normal individuals and included cerebrospinal fluid, magnetic resonance imaging, and cognitive measures, and validated in an independent cohort.
Higher baseline AD progression risk scores (hazard ratio = 2.70, P < 0.001) were associated with greater risks of progression to clinical symptoms of mild cognitive impairment (MCI). Baseline scores had an area under the curve of 0.83 (95% confidence interval: 0.75 to 0.91) for identifying subjects who progressed to MCI/dementia within 5 years. The validation procedure, using data from the Alzheimer's Disease Neuroimaging Initiative, demonstrated accuracy of prediction across the AD spectrum.
The derived risk score provides high predictive accuracy for identifying which individuals with normal cognition are likely to show clinical decline due to AD within 5 years.
识别认知正常但有进展为症状性阿尔茨海默病(AD)高风险的个体对于早期干预至关重要。
使用无监督机器学习方法得出 AD 风险评分。该评分使用来自 226 名认知正常个体的脑脊液、磁共振成像和认知测量数据开发,并在独立队列中进行了验证。
较高的基线 AD 进展风险评分(风险比=2.70,P<0.001)与进展为轻度认知障碍(MCI)的临床症状的风险增加相关。基线评分对 5 年内进展为 MCI/痴呆的受试者的识别具有 0.83(95%置信区间:0.75 至 0.91)的曲线下面积。使用来自阿尔茨海默病神经影像学倡议的数据进行的验证程序表明,该评分在 AD 谱中具有预测准确性。
所推导的风险评分对于识别在 5 年内由于 AD 而出现临床衰退的认知正常个体具有很高的预测准确性。